Novaterra

Novaterra positions itself as an evergreen investment vehicle, suggesting a permanent-capital orientation that prizes long-duration ownership over the standard ten-year fund cycle. For healthcare founders, evergreen structures can be attractive when therapeutic timelines, regulatory cycles or services scaling extend well beyond traditional VC patience windows. However, the public footprint is thin: there is no disclosed healthcare sub-vertical thesis, AI focus, stage preference or check size, and the Crunchbase reference suggests possible studio or accelerator origins rather than a pure financial investor. Plausible check sizes for an evergreen vehicle of this profile range from $250K to a few million at entry, with the ability to follow on across many years rather than the next round. The firm is most likely a fit for founders building durable, cash-generative healthcare businesses (services rollups, specialty care platforms, B2B software with recurring revenue) where compounding ownership over a decade-plus makes sense. It is poorly suited for founders running a classic venture playbook of fast burn, big rounds, IPO exit, since evergreen vehicles often resist that velocity. Pre-clinical biotech or capital-intensive devices are also unlikely fits. Without a clear named partner or thesis page in the source data, the realistic path in is a direct LinkedIn approach to firm principals, supported by a clear articulation of why your business benefits from patient capital rather than typical fund timelines. Founders should explicitly ask about hold-period expectations, exit philosophy and capacity for ongoing follow-on before investing serious diligence energy.